FBRX - Kadmon Adagio top weakly healthcare gainers; Forte Biosciences and Humanigen trail

Healthcare stocks in the S&P 500 underperformed the ~1.7% loss in the broader index to end ~2.7% lower over the holiday-shortened week to record their worst weekly performance since November. Among healthcare stocks with more than $300M market cap and over 100K average daily volume in the sector over the past five sessions, Kadmon Holdings (NASDAQ:KDMN) jumped ~68.0% thanks to an acquisition offer made by Sanofi (NASDAQ:SNY). Seeking Alpha contributor Avisol Capital Partners followed up with a bullish thesis on the biotech, arguing that its stock price “was artificially kept down by short-sellers.” Buoyed by a post-IPO high reached on Friday, Adagio Therapeutics (NASDAQ:ADGI) ended ~50.4% higher over the five-day period to record another strong weekly performance. News of an upcoming presentation of its experimental lung cancer therapy was enough for Innate Pharma (NASDAQ:IPHA) to add ~44.0%, while Surrozen (NASDAQ:SRZN), which went public in August via a SPAC merger with Consonance-HFW Acquisition, followed up with a gain of ~39.0%. Meanwhile, IVERIC bio

For further details see:

Kadmon, Adagio top weakly healthcare gainers; Forte Biosciences and Humanigen trail